Menopause Society Certified Practitioner
Competency Examination (MSCP)
2026/2027 | Brand New
Questions,Answers With Complete Solutions
Guaranteed Pass | Graded A+
Q1. According to STRAW+10, which bleeding criterion defines the late menopausal transition
(Stage -1)?
A. A persistent difference of ≥7 days in consecutive cycle lengths
B. Amenorrhea of ≥60 days but <12 months [CORRECT]
C. Amenorrhea of ≥12 consecutive months
Correct Answer: B
Rationale: Correct because STRAW+10 Stage -1 is defined by an episode of amenorrhea lasting
≥60 days. A describes Stage -2 (early transition). C defines postmenopause.
Q2. A 55-year-old woman is 4 years past menopause and requests hormone therapy for
vasomotor symptoms. She has no contraindications. According to the timing hypothesis, her risk
profile is:
A. Favorable, because initiation is within 10 years of menopause and under age 60 [CORRECT]
B. Elevated, because any HT after age 50 increases cardiovascular risk
C. Neutral, because timing has no effect on outcomes
Correct Answer: A
Rationale: Correct because the timing hypothesis supports favorable cardiovascular outcomes
when HT is initiated within 10 years of menopause or before age 60 . B contradicts the evidence.
C is incorrect because timing strongly modifies risk.
,Q3. A 62-year-old woman with moderate-to-severe dyspareunia and recurrent urinary tract
infections has been using vaginal moisturizers without relief. She has no history of breast cancer
or VTE. What is the most appropriate next step?
A. Systemic oral estrogen
B. Low-dose vaginal estrogen [CORRECT]
C. Oral ospemifene
Correct Answer: B
Rationale: Correct because low-dose vaginal estrogen is first-line for moderate-to-severe GSM,
including urinary symptoms, and is effective for recurrent UTIs . Systemic estrogen is not
needed for isolated GSM. Ospemifene is an alternative but vaginal estrogen is preferred first-
line.
Q4. A 58-year-old woman has a DEXA T-score of -2.1 at the femoral neck. According to
osteoporosis diagnostic criteria, this represents:
A. Normal bone density
B. Osteopenia [CORRECT]
C. Osteoporosis
Correct Answer: B
Rationale: Correct because a T-score between -1.0 and -2.5 defines osteopenia. Osteoporosis
requires T-score ≤ -2.5.
Q5. A 54-year-old woman with a history of breast cancer (treated 3 years ago, currently on an
aromatase inhibitor) has severe hot flashes. She cannot take estrogen. Which non-hormonal
option is FDA-approved for VMS?
A. Paroxetine
B. Fezolinetant [CORRECT]
C. Gabapentin
Correct Answer: B
Rationale: Correct because fezolinetant is a neurokinin-3 receptor antagonist specifically FDA-
approved for VMS . Paroxetine is an SSRI with evidence but is not FDA-approved specifically
for VMS in this context. Gabapentin is used off-label.
, Q6. Which of the following best describes the "window of opportunity" for hormone therapy
regarding cardiovascular risk?
A. Initiation within 10 years of menopause or before age 60 [CORRECT]
B. Initiation at any age if symptoms are severe
C. Initiation only after age 65 for cardioprotection
Correct Answer: A
Rationale: Correct because the timing hypothesis states that HT initiated within 10 years of
menopause or before age 60 confers a favorable cardiovascular profile .
Q7. A 50-year-old woman with premature ovarian insufficiency (POI) is diagnosed. Which
statement about HT in POI is correct?
A. HT is contraindicated because she is under 50
B. HT is recommended until at least the average age of natural menopause [CORRECT]
C. HT should be avoided because POI has no cardiovascular risk
Correct Answer: B
Rationale: Correct because women with POI require HT until at least the average age of natural
menopause (approximately 51-52) to protect bone and cardiovascular health.
Q8. A 60-year-old woman asks about her risk of VTE with hormone therapy. Which route of
estrogen administration is associated with the lowest VTE risk?
A. Oral conjugated equine estrogen
B. Transdermal estradiol [CORRECT]
C. Oral estradiol
Correct Answer: B
Rationale: Correct because transdermal estrogen bypasses first-pass hepatic metabolism and is
associated with no increased VTE risk compared with oral formulations .
Q9. A 56-year-old woman has a FRAX 10-year major osteoporotic fracture risk of 18%. She has
no prior fracture. According to osteoporosis treatment guidelines, what is the appropriate action?
A. Reassure her that no treatment is needed
B. Consider pharmacotherapy [CORRECT]
C. Repeat DEXA in 5 years without intervention
Competency Examination (MSCP)
2026/2027 | Brand New
Questions,Answers With Complete Solutions
Guaranteed Pass | Graded A+
Q1. According to STRAW+10, which bleeding criterion defines the late menopausal transition
(Stage -1)?
A. A persistent difference of ≥7 days in consecutive cycle lengths
B. Amenorrhea of ≥60 days but <12 months [CORRECT]
C. Amenorrhea of ≥12 consecutive months
Correct Answer: B
Rationale: Correct because STRAW+10 Stage -1 is defined by an episode of amenorrhea lasting
≥60 days. A describes Stage -2 (early transition). C defines postmenopause.
Q2. A 55-year-old woman is 4 years past menopause and requests hormone therapy for
vasomotor symptoms. She has no contraindications. According to the timing hypothesis, her risk
profile is:
A. Favorable, because initiation is within 10 years of menopause and under age 60 [CORRECT]
B. Elevated, because any HT after age 50 increases cardiovascular risk
C. Neutral, because timing has no effect on outcomes
Correct Answer: A
Rationale: Correct because the timing hypothesis supports favorable cardiovascular outcomes
when HT is initiated within 10 years of menopause or before age 60 . B contradicts the evidence.
C is incorrect because timing strongly modifies risk.
,Q3. A 62-year-old woman with moderate-to-severe dyspareunia and recurrent urinary tract
infections has been using vaginal moisturizers without relief. She has no history of breast cancer
or VTE. What is the most appropriate next step?
A. Systemic oral estrogen
B. Low-dose vaginal estrogen [CORRECT]
C. Oral ospemifene
Correct Answer: B
Rationale: Correct because low-dose vaginal estrogen is first-line for moderate-to-severe GSM,
including urinary symptoms, and is effective for recurrent UTIs . Systemic estrogen is not
needed for isolated GSM. Ospemifene is an alternative but vaginal estrogen is preferred first-
line.
Q4. A 58-year-old woman has a DEXA T-score of -2.1 at the femoral neck. According to
osteoporosis diagnostic criteria, this represents:
A. Normal bone density
B. Osteopenia [CORRECT]
C. Osteoporosis
Correct Answer: B
Rationale: Correct because a T-score between -1.0 and -2.5 defines osteopenia. Osteoporosis
requires T-score ≤ -2.5.
Q5. A 54-year-old woman with a history of breast cancer (treated 3 years ago, currently on an
aromatase inhibitor) has severe hot flashes. She cannot take estrogen. Which non-hormonal
option is FDA-approved for VMS?
A. Paroxetine
B. Fezolinetant [CORRECT]
C. Gabapentin
Correct Answer: B
Rationale: Correct because fezolinetant is a neurokinin-3 receptor antagonist specifically FDA-
approved for VMS . Paroxetine is an SSRI with evidence but is not FDA-approved specifically
for VMS in this context. Gabapentin is used off-label.
, Q6. Which of the following best describes the "window of opportunity" for hormone therapy
regarding cardiovascular risk?
A. Initiation within 10 years of menopause or before age 60 [CORRECT]
B. Initiation at any age if symptoms are severe
C. Initiation only after age 65 for cardioprotection
Correct Answer: A
Rationale: Correct because the timing hypothesis states that HT initiated within 10 years of
menopause or before age 60 confers a favorable cardiovascular profile .
Q7. A 50-year-old woman with premature ovarian insufficiency (POI) is diagnosed. Which
statement about HT in POI is correct?
A. HT is contraindicated because she is under 50
B. HT is recommended until at least the average age of natural menopause [CORRECT]
C. HT should be avoided because POI has no cardiovascular risk
Correct Answer: B
Rationale: Correct because women with POI require HT until at least the average age of natural
menopause (approximately 51-52) to protect bone and cardiovascular health.
Q8. A 60-year-old woman asks about her risk of VTE with hormone therapy. Which route of
estrogen administration is associated with the lowest VTE risk?
A. Oral conjugated equine estrogen
B. Transdermal estradiol [CORRECT]
C. Oral estradiol
Correct Answer: B
Rationale: Correct because transdermal estrogen bypasses first-pass hepatic metabolism and is
associated with no increased VTE risk compared with oral formulations .
Q9. A 56-year-old woman has a FRAX 10-year major osteoporotic fracture risk of 18%. She has
no prior fracture. According to osteoporosis treatment guidelines, what is the appropriate action?
A. Reassure her that no treatment is needed
B. Consider pharmacotherapy [CORRECT]
C. Repeat DEXA in 5 years without intervention
